(August 25, 2020)--New York, NY--Cytovia Therapeutics, an emerging biopharmaceutical company and the New York Stem Cell Foundation (NYSCF) Research Institute today announced the filing of a provisional patent application with the U.S. Patent & Trademark Office (USPTO) for the differentiation of Natural Killer (NK) cells from induced pluripotent stem cells (iPSCs). The NYSCF Research Institute is a pioneer and acknowledged leader in stem cell technology, having developed the NYSCF Global Stem Cell Array®, the premier automated robotic platform for reprogramming skin or blood into induced pluripotent stem cells (iPSCs) and differentiating them into disease-relevant cell types.

 

The number of immunotherapies in clinical trial rolls over 5000 now, and immunology has become a common approach in some cancers. Cell technologies, as a growing sub-field in the immunotherapy landscape, have progressed considerably and now represent a $26 billion financial opportunity by 2030, according to a report by Roots Analysis.

In a recent study published in Nature Communications, scientists from Cornell University made new findings in common and fatal gastric cancer research. In the United States, the incidence of gastroesophageal cancer increased 2.5-fold from the 1970s to the early 2000s, however, from the 1950s, the number of all patients with gastric cancer decreased by more than 80%; despite this, gastric cancer is still the fifth most common cancer and the third leading cause of cancer death worldwide.

Oxford Global’s 13th Annual Proteins & Antibodies Congress will be attended by over 450 visionary leaders to network about the latest developments & participate in presentations from the areas of engineering, bioanalysis, biotherapeutics and bispecifics.

New for 2020 is the introduction of the kick-off sessions, providing an interactive experience for delegates through roundtable & panel discussions.